Effects of hormone treatment on hemostasis variables

Climacteric

Volumn 10, Issue SUPPL. 2, 2007, Pages 32-37

  Kluft, C ^a,b  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Estrogen; Hemostasis; Hormone treatment; Inflammation; Menopause; Raloxifene; Tibolone; Venous thrombosis

Indexed keywords

ANTITHROMBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PROTEIN S; RALOXIFENE; TAMOXIFEN; TIBOLONE; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; ARTERY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DISEASE MARKER; DOSE RESPONSE; DRUG DOSE INCREASE; ESTROGEN THERAPY; HEALTH SURVEY; HEMOSTASIS; HORMONAL THERAPY; HUMAN; INFLAMMATION; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; VEIN; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; ETHINYL ESTRADIOL; FEMALE; HEMOSTASIS; HUMANS; INFLAMMATION; NORPREGNENES; PROGESTINS; RALOXIFENE; TAMOXIFEN; VENOUS THROMBOEMBOLISM;

EID: 34548825151     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701598548     Document Type: Conference Paper

References (21)

1. Gaspard U, Jespersen J, Kluft C, Mattson L-A, Samsioe G, Skouby SO. Consensus development meeting: metabolic aspects of oral contraceptives of relevance for cardiovascular diseases. Am J Obstet Gynecol 1990;162:1335-7
2. Kluft C, Jespersen J, de Maat MPM, Bladbjerg E-M, Skouby SO. Effect of genomics on venous thrombosis: relation to sex steroids. Menopausal Med 2006;13:1-5
3. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-500
4. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006;13:643-50
5. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-21
6. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-25
7. Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. Thromb Res 2006 Dec 5;[Epub ahead of print]
8. Sgarabotto M, Baldini M, Dei Cas A, et al. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study. Thromb Res 2007;119:85-91
9. Cosman F, Baz-Hecht M, Cushman M, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 2005;116:1-13
10. Kluft C, de Maat MP, Heinemann LA, Spannagl M, Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet 1999;354:832-3
11. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Br Med J 2001;323:131-4
12. Bray JD, Jelinsky S, Ghatge R, et al. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol 2005;97:328-41
13. Barnes JF, Farish E, Rankin M, Hart DM. Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine. Menopause 2005;12:92-8
14. Cicinelli E, Ranieri G, Maffei S, et al. Long-term effects of tibolone on circulating levels of vascular cell adhesion molecules and E-selectin in postmenopausal women. Fertil Steril 2006;86:899-904
15. Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006;53:252-9
16. Blum A. Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women. Am J Cardiol 2000;86:892-5
17. Hemelaar M, van der Mooren MJ, van Baal WM, Schalkwijk CG, Kenemans P, Stehouwer CD. Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women. Menopause 2005;12:526-35
18. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2002;106:1771-6
19. Sumino H, Ichikawa S, Kasama S, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006;189:436-42
20. Seljeflot I, Arnesen H, Hofstad AE, Os I. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thromb Haemost 2000;83:944-8
21. Kennedy G, McLaren M, Belch JJ, Seed M. Elevated levels of sE-selectin in post-menopausal females are decreased by hormone replacement therapy to levels observed in pre-menopausal females. Thromb Haemost 1999;82:1433-6